Biotechnology company Sequenta has launched a new online portal for physicians geared toward minimal residual disease detection and trends for patients with lymphoid cancers.
The ClonoSIGHT Secure Portal offers physicians a view of patients' MRD status and level, and also features an interactive graph allowing them to evaluate patients' MRD trend over time.
Clinicians can also download graphs and test reports into the EHR and track the status of ordered tests.
More articles on health IT:
HHS announces 3rd cohort of entrepreneurs-in-residence
13 recent vendor contracts, go-lives
Financial incentives, clinical information exchange top lists of reasons for EHR adoption